Executive leadership at ENTO.
Board of directors at ENTO.
Research analysts covering ENTO.
Recent press releases and 8-K filings for ENTO.
Entero Therapeutics Changes Name to GridAI Technologies Amidst Board Resignations
ENTO
Board Change
M&A
- Entero Therapeutics, Inc. changed its corporate name to GridAI Technologies Corp. and its ticker symbol from ENTO to GRDX, effective December 1, 2025. This change follows the acquisition of GRID AI Corp, an AI-driven software and controls platform.
- Eric Corbett resigned from the Board of Directors on November 28, 2025, citing fundamental disagreements with Management and the Board, including concerns about potentially inaccurate financial statements, inadequate due diligence during the GRID AI acquisition, and misleading press releases.
- Richard Paolone also resigned from the Board of Directors on November 28, 2025. In connection with his departure, the company entered into a separation agreement to pay Mr. Paolone $500,000 along with his legal fees.
Dec 4, 2025, 10:21 PM
Entero Therapeutics, Inc. Enters into Private Placement Agreement
ENTO
Debt Issuance
New Projects/Investments
- On October 17, 2025, Entero Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement offering of up to $5,000,000 in gross proceeds, consisting of Promissory Notes and common stock purchase warrants.
- An initial closing occurred on October 17, 2025, where the company sold a Promissory Note with a principal amount of $500,000 and a Warrant to purchase up to 200,000 shares of common stock for $500,000.
- The Promissory Note has a maturity date of one year and one day from its issuance, is not convertible, and does not bear interest.
- The Warrants are exercisable upon stockholder approval, have an exercise price of $2.50 per share, and expire five years from the stockholder approval date, with a maximum of 1,520,000 Warrant Shares potentially issuable.
- The net proceeds from the offering are intended for general corporate purposes, including working capital and potential acquisitions.
Oct 22, 2025, 8:01 PM
Entero Therapeutics Acquires GRID AI
ENTO
M&A
New Projects/Investments
Delisting/Listing Issues
- Entero Therapeutics, Inc. (ENTO) acquired 100% of GRID AI Corp on October 1, 2025, a grid-edge, AI-driven software and device platform, positioning ENTO in the high-growth AI energy-infrastructure market.
- Following the acquisition, and subject to shareholder approval, former GRID AI shareholders will own approximately 82.5% of the fully diluted ENTO common stock, while existing ENTO shareholders will retain approximately 17.5%.
- The transaction involved an exchange of 424,348 shares of ENTO common stock and 38,801,546 shares of Series H Non-Voting Convertible Preferred Stock.
- ENTO believes the Share Exchange has helped it regain compliance with Nasdaq's minimum stockholders' equity requirement of at least $2.5 million.
Oct 6, 2025, 8:39 PM
Entero Therapeutics Appoints Jason D. Sawyer as Interim CEO
ENTO
CEO Change
Executive Compensation
Management Change
- Entero Therapeutics, Inc. (ENTO) appointed Jason D. Sawyer as its non-employee interim Chief Executive Officer through a consulting agreement with Access Alternative Group S.A..
- The consulting agreement was dated September 8, 2025, and became effective on September 4, 2025.
- Mr. Sawyer will receive $12,500 per month for his services, with the engagement renewable on a month-to-month basis.
- The Company will defend and indemnify Mr. Sawyer in his capacity as CEO to the fullest extent permitted by Delaware General Corporation Law.
Sep 12, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more